Neurogenic Intermittent Claudication Evaluation Study (NICE)

This study is currently recruiting participants.
Verified March 2013 by Medtronic Spinal & Biologics ECA
Sponsor:
Information provided by (Responsible Party):
Medtronic Spinal & Biologics ECA
ClinicalTrials.gov Identifier:
NCT00905359
First received: May 18, 2009
Last updated: March 12, 2013
Last verified: March 2013

May 18, 2009
March 12, 2013
January 2010
May 2014   (final data collection date for primary outcome measure)
Mean percentage change from baseline in Physical Function at 1 year follow-up using the patient completed Zurich Claudication Questionnaire [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00905359 on ClinicalTrials.gov Archive Site
  • Mean percentage change from baseline in Physical Function, using the patient completed Zurich Claudication Questionnaire [ Time Frame: 14d, 6w, 6, 24, 36, 48m ] [ Designated as safety issue: No ]
  • Outcomes of the Symptom Severity and Patient Satisfaction domains of the patient completed Zurich Claudication Questionnaire [ Time Frame: 14d, 6w, 6, 12, 24, 36, 48m ] [ Designated as safety issue: No ]
  • Mean percentage change from baseline in Leg Pain VAS Scores [ Time Frame: 14d, 6w, 6, 12, 24, 36, 48m ] [ Designated as safety issue: No ]
  • QoL related outcomes using the patient completed SF-36 v2 questionnaire [ Time Frame: 14d, 6w, 6, 12, 24, 36, 48m ] [ Designated as safety issue: No ]
  • Assessment of the radiological changes in the stenotic region. [ Time Frame: 12, 24, 48 months ] [ Designated as safety issue: No ]
  • Percentage of patients requiring surgical intervention at index level [ Time Frame: Full follow up period ] [ Designated as safety issue: Yes ]
  • Proportion of subjects with complications at the secondary surgical intervention [ Time Frame: Full follow up period ] [ Designated as safety issue: Yes ]
  • Proportion of subjects with Serious Adverse Device Effects [ Time Frame: Full follow up period ] [ Designated as safety issue: Yes ]
  • Determining if there is a correlation between sagittal balance or other radiological findings and the clinical outcomes [ Time Frame: 12, 24, 48 months ] [ Designated as safety issue: No ]
  • Proportion of subjects with improvement of symptoms, symptoms recurrence, decreased therapeutic response, no therapeutic response and treatment failure [ Time Frame: 14d, 6w, 6, 12, 24, 36, 48m ] [ Designated as safety issue: Yes ]
  • Mean percentage change from baseline in Physical Function, using the patient completed Zurich Claudication Questionnaire [ Time Frame: 14d, 6w, 6, 24, 36, 48m ] [ Designated as safety issue: No ]
  • Mean percentage change from baseline in Symptom Severity, using the patient completed Zurich Claudication Questionnaire [ Time Frame: 14d, 6w, 6, 12, 24, 36, 48m ] [ Designated as safety issue: No ]
  • Percentage of patients being satisfied with the treatment assessed using the patient completed Zurich Claudication Questionnaire [ Time Frame: 14d, 6w, 6, 12, 24, 36, 48m ] [ Designated as safety issue: No ]
  • Mean percentage change from baseline in Leg Pain VAS Scores [ Time Frame: 14d, 6w, 6, 12, 24, 36, 48m ] [ Designated as safety issue: No ]
  • Mean percentage change from baseline in Quality of Life using the patient completed SF-36 v2 questionnaire [ Time Frame: 14d, 6w, 6, 12, 24, 36, 48m ] [ Designated as safety issue: No ]
  • Changes is stenosis of the spinal canal assessed by MRI. [ Time Frame: 12, 24, 48 months ] [ Designated as safety issue: No ]
  • Changes in bony structures assessed by CT [ Time Frame: 12, 24, 48 months ] [ Designated as safety issue: No ]
  • Percentage of patients requiring surgical intervention at index level [ Time Frame: Full follow up period ] [ Designated as safety issue: Yes ]
  • Proportion of subjects with complications at the secondary surgical intervention [ Time Frame: Full follow up period ] [ Designated as safety issue: Yes ]
  • Proportion of subjects with Serious Adverse Device Effects [ Time Frame: Full follow up period ] [ Designated as safety issue: Yes ]
  • Determining if there is a correlation between sagittal balance or other radiological findings and the clinical outcomes [ Time Frame: 12, 24, 48 months ] [ Designated as safety issue: No ]
  • Proportion of subjects with improvement of symptoms, symptoms recurrence, decreased therapeutic response, no therapeutic response and treatment failure [ Time Frame: 14d, 6w, 6, 12, 24, 36, 48m ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Neurogenic Intermittent Claudication Evaluation Study
A Multicenter Prospective Randomized Controlled Clinical Trial to Evaluate the Effectiveness and Safety of the Aperius™ PercLID™ System Versus Standalone Decompressive Surgery in Degenerative Lumbar Spinal Stenosis With Neurogenic Intermittent Claudication

The objective of the NICE study is to provide clinical evidence proving that the Aperius™ PercLID™ System is safe and non-inferior to standalone decompressive surgery with regards to clinical outcomes in patients suffering from Degenerative Lumbar Spinal Stenosis with Neurogenic Intermittent Claudication, relieved by flexion.

The NICE study is a Multicenter Prospective Randomized Controlled Clinical Trial to Evaluate the Effectiveness and Safety of the Aperius™ PercLID™System Versus Standalone Decompressive Surgery in Degenerative Lumbar Spinal Stenosis with Neurogenic Intermittent Claudication.

DLSS patients suffering from NIC that would be candidates for surgical treatment without stabilization and/or fusion can be offered participation in the study. After randomization, a total of up to 280 patients will be treated with either the Aperius™ PercLID™ System or Standalone Decompressive Surgery (SDS).

The patient will undergo a study visit at screening / baseline and at 14 days, 6 weeks, 6, 12, 24, 36 and 48 months after surgery. Safety data will be collected during surgery and throughout the 48 months follow up. Procedural details will be collected during surgery and also duration of hospital stay will be collected. At screening / baseline and all follow up visits a physical examination will be performed, the use of pain medication will be documented and the subject will be asked to complete a pain VAS scale (back - leg - buttock / groin pain) and questionnaires (SF36 v2 and Zurich Claudication Questionnaire).

Study subjects are required to undergo X-ray, CT and MRI and fluoroscopy procedures at specified time points during the study.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Spinal Stenosis
Procedure: Aperius™ PercLID™ System and Standalone Decompressive Surgery

Aperius™ PercLID™ System: implantation with the Interspinous Process Device Aperius.

Standalone Decompressive Surgery: lumbar decompressive surgery without instrumentation or fusion

  • Active Comparator: Aperius™ PercLID™ System
    Aperius™ PercLID™ System arm. Patients randomized to this arm will undergo treatment with the Aperius™ PercLID™ System.
    Intervention: Procedure: Aperius™ PercLID™ System and Standalone Decompressive Surgery
  • Active Comparator: Standalone Decompressive Surgery
    Patients randomized to this arm will receive Standalone Decompressive Surgery, defined as decompressive surgery without instrumentation or fusion.
    Intervention: Procedure: Aperius™ PercLID™ System and Standalone Decompressive Surgery
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
280
December 2015
May 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Presence of symptomatic DLSS
  • Presence of NIC
  • Patient would be candidate for Standalone Decompressive Surgery
  • Patient has signed Informed Consent form (ICF)
  • Patient is 21 years old or older

Exclusion Criteria:

  • Previous lumbar surgery
  • Patient is candidate for instrumented Decompressive Surgery
  • Patient has back pain without leg pain
  • Degenerative Spondylolisthesis greater than grade 1 (Meyerding)
  • Symptomatic DLSS at more than 2 levels in the lumbar region
  • Spinal stenosis is present at L5-S1 level
Both
21 Years and older
No
Contact: C. Beelen, Study Manager nice.studyregistration@medtronic.com
Contact: M. Leenders, Study Manager nice.studyregistration@medtronic.com
Australia,   Belgium,   Denmark,   France,   Germany,   Iceland,   Italy,   Netherlands,   Poland,   Singapore,   Sweden,   United Kingdom
 
NCT00905359
CIP 0002 AP
Yes
Medtronic Spinal & Biologics ECA
Medtronic Spinal & Biologics ECA
Not Provided
Not Provided
Medtronic Spinal & Biologics ECA
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP